Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for patients with genetically defined cancers. Its lead product, KOMZIFTI (ziftomenib), received FDA approval for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The company is pursuing additional indications for ziftomenib, including frontline AML and combination therapies, and has a collaboration with Kyowa Kirin Co., Ltd. for global development.
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-092567 | EDGAR | 96K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029975 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021094 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0000950170-23-004107 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001967 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001564590-21-007822 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001564590-20-006391 | EDGAR | — |
| 2019-03-05 | 2018-12-31 | 0001564590-19-006263 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005293 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001564590-17-004291 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001193125-25-263589 | EDGAR | 58K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105051 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0000950170-25-061848 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123363 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093997 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052136 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058173 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040556 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020526 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021605 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0000950170-22-014251 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007404 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001193125-26-092465 | EDGAR | 4K words |
| 2026-01-29 | 0001193125-26-029705 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009649 | EDGAR | — |
| 2025-12-02 | 0001193125-25-304559 | EDGAR | — |
| 2025-11-13 | 0001193125-25-280255 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263491 | EDGAR | — |
| 2025-10-24 | 0001193125-25-249348 | EDGAR | — |
| 2025-10-16 | 0001193125-25-241416 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105024 | EDGAR | — |
| 2025-07-01 | 0001193125-25-153393 | EDGAR | — |
256 total filings indexed. 224 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001422143 |
| Ticker | KURA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.kuraoncology.com |
| Listed | 2015-08-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report